Table 1.
Summary of representative clinical phase three trials on PARP inhibitors in prostate cancer.
| Trial | PROfound | PROpel | TALAPRO2 | |||||
|---|---|---|---|---|---|---|---|---|
| Treatment | Olaparib | Abiraterone/ Enzalutamide |
Olaparib + Abiraterone | Placecbo + Abiraterone |
Talazoparib + Enzalutamide |
Placebo + Enzalutamide |
||
| Patient eligibility | mCRPC refractory against docetaxel and either abiraterone/enzalutamide | mCRPC without abiraterone and other second-generation AR inhibitor treatment (docetaxel was allowed as a neoadjuvant or adjuvant treatment after localized disease or as a first-line treatment for mHSPC) | mCRPC without second generation AR inhibitors treatment (enzalutamide, apalutamide, darolutamide); docetaxel and abiraterone was allowed as a treatment for mHSPC | |||||
| Genetic background | BRCA1/2, ATM | 12 HRR-related genes other than BRCA1/2, ATM | BRCA1/2, ATM | 12 HRR-related genes other than BRCA1/2, ATM | All comers | All comers | ||
| Number of patients | 162 | 94 | 83 | 48 | 399 | 397 | 402 | 403 |
| Primary endpoint | rPFS of patients with BRCA1/2 or ATM mutations | rPFS | rPFS | |||||
| 7.4 ms | - | 3.6 ms | - | 24.8 ms | 16.6 ms | NR | 21.9 ms | |
| HR, 0.34; (CI, 0.25–0.47) p < 0.001 | HR, 0.66; (CI, 0.55–0.81) p < 0.0001 | HR, 0.63; (CI, 0.51–0.78) p < 0.001 | ||||||
AR: androgen receptor, mCRPC: metastatic castration-resistant prostate cancer, rPFS: radiological progression-free survival, mHSPC: metastatic hormone-sensitive prostate cancer, HR: hazard ratio, NR: not reach.